Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
$10.93
$4.51
$20.20
$236.61M0.4162,237 shs171,500 shs
Evolus, Inc. stock logo
EOLS
Evolus
$9.73
+0.7%
$9.85
$8.67
$17.82
$627.39M0.97761,589 shs555,550 shs
MannKind Corporation stock logo
MNKD
MannKind
$3.80
-0.5%
$4.15
$3.51
$7.63
$1.15B0.962.44 million shs1.80 million shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.01
+233.3%
$0.03
$0.00
$6.93
$241K1.318.09 million shs54,905 shs
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$7.95
+3.2%
$6.71
$5.04
$16.74
$1.24B-1.011.30 million shs2.57 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
0.00%0.00%0.00%0.00%0.00%
Evolus, Inc. stock logo
EOLS
Evolus
+4.32%+4.89%+0.10%+2.66%-13.52%
MannKind Corporation stock logo
MNKD
MannKind
+5.52%+5.52%-12.59%-17.67%-28.60%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-84.66%-89.02%-89.20%-89.20%-99.95%
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
+10.79%+14.07%+9.22%+40.51%+43.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
3.9265 of 5 stars
3.50.00.03.52.33.30.6
MannKind Corporation stock logo
MNKD
MannKind
2.5436 of 5 stars
3.61.00.00.00.51.71.9
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
4.3602 of 5 stars
3.15.00.04.31.12.50.6
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
4.439 of 5 stars
3.51.00.04.82.54.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
0.00
N/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
3.00
Buy$23.75144.09% Upside
MannKind Corporation stock logo
MNKD
MannKind
3.29
Buy$10.33171.93% Upside
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
2.20
Hold$3.3336,937.04% Upside
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
2.92
Moderate Buy$20.50157.86% Upside

Current Analyst Ratings Breakdown

Latest WVE, SYRS, MNKD, ADRO, and EOLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$18.00
6/11/2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$14.00
5/8/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
4/29/2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$10.00
4/17/2025
Evolus, Inc. stock logo
EOLS
Evolus
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
4/10/2025
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
4/10/2025
MannKind Corporation stock logo
MNKD
MannKind
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$12.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
$17.26M0.00N/AN/A$4.07 per share0.00
Evolus, Inc. stock logo
EOLS
Evolus
$266.27M2.36N/AN/A$0.09 per share108.11
MannKind Corporation stock logo
MNKD
MannKind
$285.50M4.05$0.15 per share26.08($0.29) per share-13.10
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K0.63N/AN/A$0.79 per share0.01
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$108.30M11.42N/AN/A$1.37 per share5.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
-$82.37M-$5.15N/AN/AN/A-230.92%-101.73%-22.35%N/A
Evolus, Inc. stock logo
EOLS
Evolus
-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)
MannKind Corporation stock logo
MNKD
MannKind
$27.59M$0.1038.0016.52N/A10.12%-32.41%10.85%8/6/2025 (Estimated)
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%7/29/2025 (Estimated)
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-$97.01M-$0.84N/AN/AN/AN/A-86.49%-37.20%8/14/2025 (Estimated)

Latest WVE, SYRS, MNKD, ADRO, and EOLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.04N/AN/AN/A$77.82 millionN/A
7/30/2025Q2 2025
Evolus, Inc. stock logo
EOLS
Evolus
-$0.09N/AN/AN/A$82.18 millionN/A
5/8/2025Q1 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.03$0.04+$0.01$0.04$75.86 million$78.35 million
5/8/2025Q1 2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/A
8.91
8.91
Evolus, Inc. stock logo
EOLS
Evolus
22.00
2.34
2.16
MannKind Corporation stock logo
MNKD
MannKind
N/A
2.36
2.11
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
N/A
2.95
2.95

Institutional Ownership

CompanyInstitutional Ownership
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
49.93%
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
MannKind Corporation stock logo
MNKD
MannKind
49.55%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
89.73%

Insider Ownership

CompanyInsider Ownership
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
5.90%
Evolus, Inc. stock logo
EOLS
Evolus
5.90%
MannKind Corporation stock logo
MNKD
MannKind
2.70%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12.26%
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
23.98%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
15216.21 millionN/AOptionable
Evolus, Inc. stock logo
EOLS
Evolus
17064.48 million60.67 millionOptionable
MannKind Corporation stock logo
MNKD
MannKind
400303.93 million295.73 millionOptionable
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12026.83 million23.54 millionOptionable
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
240155.56 million118.26 millionOptionable

Recent News About These Companies

Brokerages Set WAVE Life Sciences Ltd. (NASDAQ:WVE) PT at $20.50
Wave Life Sciences: Speculative, But Promising
Wave Life Sciences Ltd. (WVE) - Yahoo Finance
Where WAVE Life Sciences Stands With Analysts

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aduro Biotech stock logo

Aduro Biotech NASDAQ:ADRO

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Evolus stock logo

Evolus NASDAQ:EOLS

$9.73 +0.07 (+0.72%)
Closing price 04:00 PM Eastern
Extended Trading
$9.80 +0.07 (+0.77%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

MannKind stock logo

MannKind NASDAQ:MNKD

$3.80 -0.02 (-0.52%)
Closing price 04:00 PM Eastern
Extended Trading
$3.80 0.00 (0.00%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.0090 +0.01 (+233.33%)
As of 03:58 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

WAVE Life Sciences stock logo

WAVE Life Sciences NASDAQ:WVE

$7.95 +0.25 (+3.25%)
Closing price 04:00 PM Eastern
Extended Trading
$8.17 +0.22 (+2.77%)
As of 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.